Increased expression of plasma mir-9-3p and let-7b-3p in methamphetamine use disorder and its clinical significance

Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals wit...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 14; no. 1; pp. 31729 - 15
Main Authors Wang, Wei, Li, Chen, Sun, Guangsheng, Qiu, Cunxi, Fan, Junyi, Jin, Yuhan, Liu, Kunpeng, Sun, Peng
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 30.12.2024
Nature Publishing Group
Nature Portfolio
Subjects
692/308
692/4017
692/617
692/699
Adult
Amphetamine-Related Disorders - blood
Bioinformatics
Biological markers
Biomarkers
Biomarkers - blood
Brain-derived neurotrophic factor
Case-Control Studies
Clinical Relevance
Correlation analysis
Diagnosis
Drug abuse
Female
Health care
Humanities and Social Sciences
Humans
Information processing
let-7b-3p
Male
Mental depression
Mental disorders
Methamphetamine
Methamphetamine - adverse effects
MicroRNAs
MicroRNAs - blood
MicroRNAs - genetics
Middle Aged
miR-9-3p
miRNA
multidisciplinary
Plasma
Public health
ROC Curve
Science
Science (multidisciplinary)
Transfection
miR-9-3p
Drug abuse
let-7b-3p
ROC curve
Biological markers
Methamphetamine
Online AccessGet full text
ISSN2045-2322
2045-2322
DOI10.1038/s41598-024-81921-x

Cover

Abstract Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals with methamphetamine use disorder and investigate the relationship between these differentially expressed miRNAs and the disorder itself, cravings for methamphetamine, and associated mental disorders. Furthermore, the study seeks to clarify the expression of downstream target molecules of specific miRNAs in the plasma of methamphetamine use disorder, assess the diagnostic utility of these miRNAs and their target molecules, explore their potential as biomarkers, and identify potential targets for the diagnosis and treatment of methamphetamine use disorder. The research subjects included 112 individuals with methamphetamine use disorder and 112 healthy controls. A questionnaire was utilized to gather baseline information on methamphetamine use disorder, assess craving for methamphetamine using a Visual Analog Scale (VAS), and evaluate anxiety (SAS) and depression (SDS) states. Employing qRT-PCR technology, we measured the expression levels of miR-9-3p and let-7b-3p in the plasma of those with the disorder. Bioinformatics tools were then used to predict downstream target molecules. Western blot analysis was conducted to quantify the levels of these target molecules in the plasma. Receiver operating characteristic (ROC) curves were utilized to evaluate the diagnostic accuracy of miRNAs and their target molecules. Additionally, we analyzed the correlation between the miRNA expression levels and the psychiatric symptoms of methamphetamine use disorder. The qRT-PCR results revealed that the expression levels of miR-9-3p and let-7b-3p were significantly elevated in the plasma of individuals with methamphetamine use disorder compared to healthy controls ( P  < 0.05). Furthermore, qRT-PCR and Western blot analyses demonstrated that transfection with miR-9-3p mimic led to overexpression of miR-9-3p, while transfection with let-7-3p mimic promoted overexpression of let-7-3p, concurrently inhibiting the protein levels of BDNF and GSK3B in cells ( P  < 0.05); ROC curve analysis indicated that the AUC for miR-9-3p was 0.782 (95% CI 0.716–0.848) and for let-7b-3p was 0.720 (95% CI 0.650–0.789). However, Spearman correlation analysis showed no significant association between the expression levels of target miRNAs and proteins and the psychiatric symptoms of methamphetamine use disorder. Notably, the combination of miR-9-3p, let-7b-3p, and BDNF exhibited high diagnostic accuracy for methamphetamine use disorder, suggesting their potential as biomarkers for its diagnosis.
AbstractList Abstract Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals with methamphetamine use disorder and investigate the relationship between these differentially expressed miRNAs and the disorder itself, cravings for methamphetamine, and associated mental disorders. Furthermore, the study seeks to clarify the expression of downstream target molecules of specific miRNAs in the plasma of methamphetamine use disorder, assess the diagnostic utility of these miRNAs and their target molecules, explore their potential as biomarkers, and identify potential targets for the diagnosis and treatment of methamphetamine use disorder. The research subjects included 112 individuals with methamphetamine use disorder and 112 healthy controls. A questionnaire was utilized to gather baseline information on methamphetamine use disorder, assess craving for methamphetamine using a Visual Analog Scale (VAS), and evaluate anxiety (SAS) and depression (SDS) states. Employing qRT-PCR technology, we measured the expression levels of miR-9-3p and let-7b-3p in the plasma of those with the disorder. Bioinformatics tools were then used to predict downstream target molecules. Western blot analysis was conducted to quantify the levels of these target molecules in the plasma. Receiver operating characteristic (ROC) curves were utilized to evaluate the diagnostic accuracy of miRNAs and their target molecules. Additionally, we analyzed the correlation between the miRNA expression levels and the psychiatric symptoms of methamphetamine use disorder. The qRT-PCR results revealed that the expression levels of miR-9-3p and let-7b-3p were significantly elevated in the plasma of individuals with methamphetamine use disorder compared to healthy controls (P < 0.05). Furthermore, qRT-PCR and Western blot analyses demonstrated that transfection with miR-9-3p mimic led to overexpression of miR-9-3p, while transfection with let-7-3p mimic promoted overexpression of let-7-3p, concurrently inhibiting the protein levels of BDNF and GSK3B in cells (P < 0.05); ROC curve analysis indicated that the AUC for miR-9-3p was 0.782 (95% CI 0.716–0.848) and for let-7b-3p was 0.720 (95% CI 0.650–0.789). However, Spearman correlation analysis showed no significant association between the expression levels of target miRNAs and proteins and the psychiatric symptoms of methamphetamine use disorder. Notably, the combination of miR-9-3p, let-7b-3p, and BDNF exhibited high diagnostic accuracy for methamphetamine use disorder, suggesting their potential as biomarkers for its diagnosis.
Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals with methamphetamine use disorder and investigate the relationship between these differentially expressed miRNAs and the disorder itself, cravings for methamphetamine, and associated mental disorders. Furthermore, the study seeks to clarify the expression of downstream target molecules of specific miRNAs in the plasma of methamphetamine use disorder, assess the diagnostic utility of these miRNAs and their target molecules, explore their potential as biomarkers, and identify potential targets for the diagnosis and treatment of methamphetamine use disorder. The research subjects included 112 individuals with methamphetamine use disorder and 112 healthy controls. A questionnaire was utilized to gather baseline information on methamphetamine use disorder, assess craving for methamphetamine using a Visual Analog Scale (VAS), and evaluate anxiety (SAS) and depression (SDS) states. Employing qRT-PCR technology, we measured the expression levels of miR-9-3p and let-7b-3p in the plasma of those with the disorder. Bioinformatics tools were then used to predict downstream target molecules. Western blot analysis was conducted to quantify the levels of these target molecules in the plasma. Receiver operating characteristic (ROC) curves were utilized to evaluate the diagnostic accuracy of miRNAs and their target molecules. Additionally, we analyzed the correlation between the miRNA expression levels and the psychiatric symptoms of methamphetamine use disorder. The qRT-PCR results revealed that the expression levels of miR-9-3p and let-7b-3p were significantly elevated in the plasma of individuals with methamphetamine use disorder compared to healthy controls (P < 0.05). Furthermore, qRT-PCR and Western blot analyses demonstrated that transfection with miR-9-3p mimic led to overexpression of miR-9-3p, while transfection with let-7-3p mimic promoted overexpression of let-7-3p, concurrently inhibiting the protein levels of BDNF and GSK3B in cells (P < 0.05); ROC curve analysis indicated that the AUC for miR-9-3p was 0.782 (95% CI 0.716–0.848) and for let-7b-3p was 0.720 (95% CI 0.650–0.789). However, Spearman correlation analysis showed no significant association between the expression levels of target miRNAs and proteins and the psychiatric symptoms of methamphetamine use disorder. Notably, the combination of miR-9-3p, let-7b-3p, and BDNF exhibited high diagnostic accuracy for methamphetamine use disorder, suggesting their potential as biomarkers for its diagnosis.
Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals with methamphetamine use disorder and investigate the relationship between these differentially expressed miRNAs and the disorder itself, cravings for methamphetamine, and associated mental disorders. Furthermore, the study seeks to clarify the expression of downstream target molecules of specific miRNAs in the plasma of methamphetamine use disorder, assess the diagnostic utility of these miRNAs and their target molecules, explore their potential as biomarkers, and identify potential targets for the diagnosis and treatment of methamphetamine use disorder. The research subjects included 112 individuals with methamphetamine use disorder and 112 healthy controls. A questionnaire was utilized to gather baseline information on methamphetamine use disorder, assess craving for methamphetamine using a Visual Analog Scale (VAS), and evaluate anxiety (SAS) and depression (SDS) states. Employing qRT-PCR technology, we measured the expression levels of miR-9-3p and let-7b-3p in the plasma of those with the disorder. Bioinformatics tools were then used to predict downstream target molecules. Western blot analysis was conducted to quantify the levels of these target molecules in the plasma. Receiver operating characteristic (ROC) curves were utilized to evaluate the diagnostic accuracy of miRNAs and their target molecules. Additionally, we analyzed the correlation between the miRNA expression levels and the psychiatric symptoms of methamphetamine use disorder. The qRT-PCR results revealed that the expression levels of miR-9-3p and let-7b-3p were significantly elevated in the plasma of individuals with methamphetamine use disorder compared to healthy controls (P < 0.05). Furthermore, qRT-PCR and Western blot analyses demonstrated that transfection with miR-9-3p mimic led to overexpression of miR-9-3p, while transfection with let-7-3p mimic promoted overexpression of let-7-3p, concurrently inhibiting the protein levels of BDNF and GSK3B in cells (P < 0.05); ROC curve analysis indicated that the AUC for miR-9-3p was 0.782 (95% CI 0.716-0.848) and for let-7b-3p was 0.720 (95% CI 0.650-0.789). However, Spearman correlation analysis showed no significant association between the expression levels of target miRNAs and proteins and the psychiatric symptoms of methamphetamine use disorder. Notably, the combination of miR-9-3p, let-7b-3p, and BDNF exhibited high diagnostic accuracy for methamphetamine use disorder, suggesting their potential as biomarkers for its diagnosis.Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals with methamphetamine use disorder and investigate the relationship between these differentially expressed miRNAs and the disorder itself, cravings for methamphetamine, and associated mental disorders. Furthermore, the study seeks to clarify the expression of downstream target molecules of specific miRNAs in the plasma of methamphetamine use disorder, assess the diagnostic utility of these miRNAs and their target molecules, explore their potential as biomarkers, and identify potential targets for the diagnosis and treatment of methamphetamine use disorder. The research subjects included 112 individuals with methamphetamine use disorder and 112 healthy controls. A questionnaire was utilized to gather baseline information on methamphetamine use disorder, assess craving for methamphetamine using a Visual Analog Scale (VAS), and evaluate anxiety (SAS) and depression (SDS) states. Employing qRT-PCR technology, we measured the expression levels of miR-9-3p and let-7b-3p in the plasma of those with the disorder. Bioinformatics tools were then used to predict downstream target molecules. Western blot analysis was conducted to quantify the levels of these target molecules in the plasma. Receiver operating characteristic (ROC) curves were utilized to evaluate the diagnostic accuracy of miRNAs and their target molecules. Additionally, we analyzed the correlation between the miRNA expression levels and the psychiatric symptoms of methamphetamine use disorder. The qRT-PCR results revealed that the expression levels of miR-9-3p and let-7b-3p were significantly elevated in the plasma of individuals with methamphetamine use disorder compared to healthy controls (P < 0.05). Furthermore, qRT-PCR and Western blot analyses demonstrated that transfection with miR-9-3p mimic led to overexpression of miR-9-3p, while transfection with let-7-3p mimic promoted overexpression of let-7-3p, concurrently inhibiting the protein levels of BDNF and GSK3B in cells (P < 0.05); ROC curve analysis indicated that the AUC for miR-9-3p was 0.782 (95% CI 0.716-0.848) and for let-7b-3p was 0.720 (95% CI 0.650-0.789). However, Spearman correlation analysis showed no significant association between the expression levels of target miRNAs and proteins and the psychiatric symptoms of methamphetamine use disorder. Notably, the combination of miR-9-3p, let-7b-3p, and BDNF exhibited high diagnostic accuracy for methamphetamine use disorder, suggesting their potential as biomarkers for its diagnosis.
Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression changes of miRNAs in the plasma of methamphetamine use disorder and elucidate the alterations in miRNA expression in the plasma of individuals with methamphetamine use disorder and investigate the relationship between these differentially expressed miRNAs and the disorder itself, cravings for methamphetamine, and associated mental disorders. Furthermore, the study seeks to clarify the expression of downstream target molecules of specific miRNAs in the plasma of methamphetamine use disorder, assess the diagnostic utility of these miRNAs and their target molecules, explore their potential as biomarkers, and identify potential targets for the diagnosis and treatment of methamphetamine use disorder. The research subjects included 112 individuals with methamphetamine use disorder and 112 healthy controls. A questionnaire was utilized to gather baseline information on methamphetamine use disorder, assess craving for methamphetamine using a Visual Analog Scale (VAS), and evaluate anxiety (SAS) and depression (SDS) states. Employing qRT-PCR technology, we measured the expression levels of miR-9-3p and let-7b-3p in the plasma of those with the disorder. Bioinformatics tools were then used to predict downstream target molecules. Western blot analysis was conducted to quantify the levels of these target molecules in the plasma. Receiver operating characteristic (ROC) curves were utilized to evaluate the diagnostic accuracy of miRNAs and their target molecules. Additionally, we analyzed the correlation between the miRNA expression levels and the psychiatric symptoms of methamphetamine use disorder. The qRT-PCR results revealed that the expression levels of miR-9-3p and let-7b-3p were significantly elevated in the plasma of individuals with methamphetamine use disorder compared to healthy controls ( P  < 0.05). Furthermore, qRT-PCR and Western blot analyses demonstrated that transfection with miR-9-3p mimic led to overexpression of miR-9-3p, while transfection with let-7-3p mimic promoted overexpression of let-7-3p, concurrently inhibiting the protein levels of BDNF and GSK3B in cells ( P  < 0.05); ROC curve analysis indicated that the AUC for miR-9-3p was 0.782 (95% CI 0.716–0.848) and for let-7b-3p was 0.720 (95% CI 0.650–0.789). However, Spearman correlation analysis showed no significant association between the expression levels of target miRNAs and proteins and the psychiatric symptoms of methamphetamine use disorder. Notably, the combination of miR-9-3p, let-7b-3p, and BDNF exhibited high diagnostic accuracy for methamphetamine use disorder, suggesting their potential as biomarkers for its diagnosis.
ArticleNumber 31729
Author Li, Chen
Qiu, Cunxi
Jin, Yuhan
Wang, Wei
Sun, Guangsheng
Liu, Kunpeng
Fan, Junyi
Sun, Peng
Author_xml – sequence: 1
  givenname: Wei
  surname: Wang
  fullname: Wang, Wei
  email: wwlnfx@163.com
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China, Key Laboratory of Drug Control Technology in Liaoning Province
– sequence: 2
  givenname: Chen
  surname: Li
  fullname: Li, Chen
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China, Key Laboratory of Drug Control Technology in Liaoning Province
– sequence: 3
  givenname: Guangsheng
  surname: Sun
  fullname: Sun, Guangsheng
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China, Key Laboratory of Drug Control Technology in Liaoning Province
– sequence: 4
  givenname: Cunxi
  surname: Qiu
  fullname: Qiu, Cunxi
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China
– sequence: 5
  givenname: Junyi
  surname: Fan
  fullname: Fan, Junyi
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China
– sequence: 6
  givenname: Yuhan
  surname: Jin
  fullname: Jin, Yuhan
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China
– sequence: 7
  givenname: Kunpeng
  surname: Liu
  fullname: Liu, Kunpeng
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China
– sequence: 8
  givenname: Peng
  surname: Sun
  fullname: Sun, Peng
  organization: Department of Drug Prohibition and Public Security, Criminal Investigation Police University of China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39738153$$D View this record in MEDLINE/PubMed
BookMark eNqNUstu1DAUjVARLaU_wAJZYsMm4GfirBCqeIxUiQ2sLce-mfHIsYOd0Onf43lQWhYIb64f5x4fn-Pn1VmIAarqJcFvCWbyXeZEdLLGlNeSdJTUuyfVBcVc1JRRevZgfl5d5bzFZQjacdI9q85Z1zJJBLuo8iqYBDqDRbCbEuTsYkBxQJPXedRodKnuajYhHSzyMNdtv1-5gEaYN3qcNjDr0QVASwZkXY7JQjqg3ZyR8S44oz3Kbh3cUKbBwIvq6aB9hqtTvay-f_r47fpLffP18-r6w01teEfnmg4GG9HxBlrTUtk2kmlmQfKeUaNJV2pPRaM5BtZLZhlppWl7LLglxRLBLqvVkddGvVVTcqNOdypqpw4bMa2VTrMzHpQWjDVENkIMPbcDlQw62xuCxSAZbmXhYkeuJUz67lZ7f09IsNonoo6JqJKIOiSidqXr_bFrWvoRrIEwJ-0fSXl8EtxGreNPRUgjG8p4YXhzYkjxxwJ5VqPLBrzXAeKSFSMCM76XXqCv_4Ju45JCcfiA2jtC94SvHkq61_L7SxQAPQJMijknGP7voSd7cgGHNaQ_d_-j6xfSX9jY
Cites_doi 10.3389/fcimb.2021.706961
10.1093/nar/gkac963
10.1080/15548627.2016.1191723
10.1007/s40263-020-00711-x
10.1164/rccm.201705-0943OC
10.1016/j.nbd.2018.05.017
10.26355/eurrev_202006_21705
10.3389/fnmol.2021.667725
10.1155/2022/9173514
10.1016/j.expneurol.2021.113795
10.1016/j.neuropharm.2015.08.045
10.1038/s41398-018-0224-5
10.1016/j.isci.2021.102058
10.1111/adb.12520
10.1080/15548627.2017.1356975
10.1093/ijnp/pyab043
10.1111/nyas.14688
10.1016/j.retram.2022.103367
10.1093/nar/27.1.29
10.1016/j.neuron.2021.08.033
10.4238/2014.July.25.12
10.1111/jnc.12006
10.1007/s11481-016-9671-z
10.1111/j.1360-0443.2005.01160.x
10.1016/j.phrs.2017.03.009
10.1093/nar/gkr254
10.1002/pro.3715
10.3389/fmicb.2022.755189
10.1016/j.pharmthera.2013.01.004
10.1093/nar/gkab1256
10.7150/thno.67227
10.1007/s00213-021-05936-2
10.1002/jev2.12177
10.3389/fpsyt.2022.897801
10.1038/aps.2016.3
10.1016/j.pneurobio.2015.09.011
10.1097/JCP.0000000000001755
10.1016/j.nbd.2019.104612
10.1093/ijnp/pyac004
10.1192/bjp.2019.173
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
Copyright Nature Publishing Group 2024
The Author(s) 2024 2024
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: Copyright Nature Publishing Group 2024
– notice: The Author(s) 2024 2024
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
ADTOC
UNPAY
DOA
DOI 10.1038/s41598-024-81921-x
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
ProQuest Biological Science Collection
Health & Medical Collection (Alumni)
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Scholarly Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 6
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
Public Health
EISSN 2045-2322
EndPage 15
ExternalDocumentID oai_doaj_org_article_a533618655fb4df283e9dbc105f83078
10.1038/s41598-024-81921-x
PMC11686234
39738153
10_1038_s41598_024_81921_x
Genre Journal Article
GrantInformation_xml – fundername: National Key R&D Program Project
  grantid: 2018YFC0807405
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PUEGO
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AARCD
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ADTOC
EJD
IPNFZ
RIG
UNPAY
ID FETCH-LOGICAL-c492t-2fc0c5946e7c7287683a3de84b32ca194b3b256a40e3b83d3178c7b054d181953
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 00:50:58 EDT 2025
Wed Oct 01 16:02:59 EDT 2025
Tue Sep 30 17:06:29 EDT 2025
Fri Sep 05 04:12:16 EDT 2025
Wed Aug 13 09:18:23 EDT 2025
Thu Apr 03 07:11:47 EDT 2025
Wed Oct 01 02:45:42 EDT 2025
Fri Feb 21 02:36:03 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords miR-9-3p
Drug abuse
let-7b-3p
ROC curve
Biological markers
Methamphetamine
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
cc-by-nc-nd
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c492t-2fc0c5946e7c7287683a3de84b32ca194b3b256a40e3b83d3178c7b054d181953
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-024-81921-x
PMID 39738153
PQID 3150195324
PQPubID 2041939
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_a533618655fb4df283e9dbc105f83078
unpaywall_primary_10_1038_s41598_024_81921_x
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11686234
proquest_miscellaneous_3150346186
proquest_journals_3150195324
pubmed_primary_39738153
crossref_primary_10_1038_s41598_024_81921_x
springer_journals_10_1038_s41598_024_81921_x
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-12-30
PublicationDateYYYYMMDD 2024-12-30
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-12-30
  day: 30
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References H Qian (81921_CR26) 2021; 238
JD Mills (81921_CR27) 2020; 134
MD Prakash (81921_CR3) 2017; 120
R Moratalla (81921_CR9) 2017; 155
81921_CR1
S Chand (81921_CR16) 2021; 10
81921_CR17
81921_CR19
81921_CR34
81921_CR30
AB Thompson (81921_CR37) 2015; 99
RT Zamanian (81921_CR4) 2018; 197
81921_CR11
A Turchinovich (81921_CR18) 2011; 39
S Jayanthi (81921_CR8) 2021; 344
B Cotto (81921_CR35) 2018; 117
Q Bu (81921_CR12) 2012; 123
B Xie (81921_CR13) 2022; 25
AC Amaral (81921_CR38) 2021; 24
T Pang (81921_CR39) 2016; 37
A Kilikevicius (81921_CR14) 2022; 50
Y Yang (81921_CR5) 2021; 11
KK Zhang (81921_CR6) 2022; 13
J Quinn (81921_CR24) 2018; 23
SJ Allen (81921_CR33) 2013; 138
81921_CR28
81921_CR29
Z Xiao (81921_CR31) 2022; 2022
Y Wang (81921_CR15) 2021; 14
KJ Siefried (81921_CR2) 2020; 34
A Liu (81921_CR10) 2021; 24
81921_CR25
81921_CR20
81921_CR21
81921_CR22
CM Jones (81921_CR23) 2022; 1508
R Huang (81921_CR7) 2017; 13
J Cabana-Domínguez (81921_CR32) 2018; 8
K Abdelkhalek (81921_CR36) 2022; 13
C McGregor (81921_CR40) 2005; 100
References_xml – volume: 11
  start-page: 706961
  year: 2021
  ident: 81921_CR5
  publication-title: Front. Cell. Infect. Microbiol.
  doi: 10.3389/fcimb.2021.706961
– ident: 81921_CR22
  doi: 10.1093/nar/gkac963
– ident: 81921_CR17
  doi: 10.1080/15548627.2016.1191723
– volume: 34
  start-page: 337
  issue: 4
  year: 2020
  ident: 81921_CR2
  publication-title: CNS Drugs
  doi: 10.1007/s40263-020-00711-x
– volume: 197
  start-page: 788
  issue: 6
  year: 2018
  ident: 81921_CR4
  publication-title: Am. J. Respir Crit. Care Med.
  doi: 10.1164/rccm.201705-0943OC
– volume: 117
  start-page: 28
  year: 2018
  ident: 81921_CR35
  publication-title: Neurobiol. Dis.
  doi: 10.1016/j.nbd.2018.05.017
– ident: 81921_CR25
  doi: 10.26355/eurrev_202006_21705
– volume: 14
  start-page: 667725
  year: 2021
  ident: 81921_CR15
  publication-title: Front. Mol. Neurosci.
  doi: 10.3389/fnmol.2021.667725
– volume: 2022
  start-page: 9173514
  year: 2022
  ident: 81921_CR31
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2022/9173514
– volume: 344
  start-page: 113795
  year: 2021
  ident: 81921_CR8
  publication-title: Exp. Neurol.
  doi: 10.1016/j.expneurol.2021.113795
– volume: 99
  start-page: 658
  year: 2015
  ident: 81921_CR37
  publication-title: Neuropharmacology
  doi: 10.1016/j.neuropharm.2015.08.045
– volume: 8
  start-page: 173
  issue: 1
  year: 2018
  ident: 81921_CR32
  publication-title: Transl Psychiatry
  doi: 10.1038/s41398-018-0224-5
– volume: 24
  start-page: 102058
  issue: 2
  year: 2021
  ident: 81921_CR38
  publication-title: iScience
  doi: 10.1016/j.isci.2021.102058
– volume: 23
  start-page: 631
  issue: 2
  year: 2018
  ident: 81921_CR24
  publication-title: Addict. Biol.
  doi: 10.1111/adb.12520
– volume: 13
  start-page: 1722
  issue: 10
  year: 2017
  ident: 81921_CR7
  publication-title: Autophagy
  doi: 10.1080/15548627.2017.1356975
– volume: 24
  start-page: 879
  issue: 11
  year: 2021
  ident: 81921_CR10
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyab043
– volume: 1508
  start-page: 3
  issue: 1
  year: 2022
  ident: 81921_CR23
  publication-title: Ann. N Y Acad. Sci.
  doi: 10.1111/nyas.14688
– ident: 81921_CR28
  doi: 10.1016/j.retram.2022.103367
– ident: 81921_CR20
  doi: 10.1093/nar/27.1.29
– ident: 81921_CR11
  doi: 10.1016/j.neuron.2021.08.033
– ident: 81921_CR19
  doi: 10.4238/2014.July.25.12
– volume: 123
  start-page: 790
  issue: 5
  year: 2012
  ident: 81921_CR12
  publication-title: J. Neurochem
  doi: 10.1111/jnc.12006
– ident: 81921_CR29
  doi: 10.1007/s11481-016-9671-z
– volume: 100
  start-page: 1320
  issue: 9
  year: 2005
  ident: 81921_CR40
  publication-title: Addiction
  doi: 10.1111/j.1360-0443.2005.01160.x
– volume: 120
  start-page: 60
  year: 2017
  ident: 81921_CR3
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2017.03.009
– volume: 39
  start-page: 7223
  issue: 16
  year: 2011
  ident: 81921_CR18
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkr254
– ident: 81921_CR21
  doi: 10.1002/pro.3715
– volume: 13
  start-page: 755189
  year: 2022
  ident: 81921_CR6
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2022.755189
– volume: 138
  start-page: 155
  issue: 2
  year: 2013
  ident: 81921_CR33
  publication-title: Pharmacol. Ther.
  doi: 10.1016/j.pharmthera.2013.01.004
– volume: 50
  start-page: 617
  issue: 2
  year: 2022
  ident: 81921_CR14
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkab1256
– ident: 81921_CR30
  doi: 10.7150/thno.67227
– volume: 238
  start-page: 3207
  issue: 11
  year: 2021
  ident: 81921_CR26
  publication-title: Psychopharmacol. (Berl)
  doi: 10.1007/s00213-021-05936-2
– volume: 10
  start-page: e12177
  issue: 14
  year: 2021
  ident: 81921_CR16
  publication-title: J. Extracell. Vesicles
  doi: 10.1002/jev2.12177
– volume: 13
  start-page: 897801
  year: 2022
  ident: 81921_CR36
  publication-title: Front. Psychiatry
  doi: 10.3389/fpsyt.2022.897801
– volume: 37
  start-page: 741
  issue: 6
  year: 2016
  ident: 81921_CR39
  publication-title: Acta Pharmacol. Sin
  doi: 10.1038/aps.2016.3
– volume: 155
  start-page: 149
  year: 2017
  ident: 81921_CR9
  publication-title: Prog Neurobiol.
  doi: 10.1016/j.pneurobio.2015.09.011
– ident: 81921_CR1
  doi: 10.1097/JCP.0000000000001755
– volume: 134
  start-page: 104612
  year: 2020
  ident: 81921_CR27
  publication-title: Neurobiol. Dis.
  doi: 10.1016/j.nbd.2019.104612
– volume: 25
  start-page: 412
  issue: 5
  year: 2022
  ident: 81921_CR13
  publication-title: Int. J. Neuropsychopharmacol.
  doi: 10.1093/ijnp/pyac004
– ident: 81921_CR34
  doi: 10.1192/bjp.2019.173
SSID ssj0000529419
Score 2.4525006
Snippet Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in expression...
Abstract Methamphetamine use disorder has emerged as a significant public health concern globally. This study endeavors to elucidate the alterations in...
SourceID doaj
unpaywall
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 31729
SubjectTerms 692/308
692/4017
692/617
692/699
Adult
Amphetamine-Related Disorders - blood
Bioinformatics
Biological markers
Biomarkers
Biomarkers - blood
Brain-derived neurotrophic factor
Case-Control Studies
Clinical Relevance
Correlation analysis
Diagnosis
Drug abuse
Female
Health care
Humanities and Social Sciences
Humans
Information processing
let-7b-3p
Male
Mental depression
Mental disorders
Methamphetamine
Methamphetamine - adverse effects
MicroRNAs
MicroRNAs - blood
MicroRNAs - genetics
Middle Aged
miR-9-3p
miRNA
multidisciplinary
Plasma
Public health
ROC Curve
Science
Science (multidisciplinary)
Transfection
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQJAQ8IH4vYyAj8casJbbT2I-AmCYkeGLS3iz_iqi0utWSiu6_352ThlYg4IGnKo2Vunff9T7Xd58JeQuLBmDBjjOnvGMyVBVzAbDsGu-VbyPXDhuFv3ydnV_Iz5f15c5RX1gTNsgDD4Y7tcBHUNO9rlsnQwvZMOrgPNCCVgE-c5svpLGdxdSg6s21rPTYJVMKddpBpsJuMi5Z1gBjm71MlAX7f8cyfy2WnHZMH5B767SyNz_s1dVOUjp7RB6ObJK-H77FY3Inpifk7nC-5M1T0kH0Y9F5DDRuxorXRJctXQFnXli6mF8zzcSK2hQoOJA1Dq_mieLB0hYcHXu7AB5K112kYRTqzKPnfUe3XZUUi0Cw5AgR9IxcnH369vGcjacsMC817xlvfelrLWex8Q2sn2ZKWBGikk5wbysNrw54kZVlFE6JAIRD-cYB1QtV3oR7Tg7SMsVDQr32ZbT4p6KDhQdXNqoo6pkvVYAf1loV5N3W4mY1iGmYvAkulBn8Y8A_JvvHbAryAZ0yjUQh7PwGwMOM8DB_g0dBjrcuNWN0dkYAC8aZc1mQN9NtiCvcLLEpLtfDGCHx0QV5MSBgmglwOCA6tSiI2sPG3lT376T596zdXVXYkiPgg0-2MPo5rz_Z4mSC2j-Y7uh_mO4luc8xXFDVsjwmB_31Or4CBta71znYbgEx7ypA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1ba9RAFB60IioiWrVGq4zgmx2aZCabyZOoWIqgTxb2bZhb7EI3iZss3f57z5nMpi5K8SkkGZJJzmW-OVdC3sGmAVCwyZmR1jDhsowZB7xsSmulrX1eGUwU_vZ9dnomvs6LeTS49TGscqsTg6J2rUUb-TEH5IIun1x86H4x7BqF3tXYQuM2uZMBVEGuLuflZGNBL5bIqpgrk3J53MN6hTlluWChEhjb7KxHoWz_v7Dm3yGTk9_0Abm3bjp9dakvLv5Ymk4ek0cRU9KPIxM8Ibd8s0_ujl0mr_bJw9E0R8eMo6ekB52AoejeUb-JcbANbWvaAZJearpcrFjFeEd14yiQlZUGzxYNxXbTGsjvB70EdErXvaculu8MoxdDT7e5lhRDQzAQCfnqGTk7-fLj8ymLvReYFVU-sLy2qS0qMfOlLWFXNZNcc-elMDy3OqvgaAAtaZF6biR3AEOkLQ0AQJcF19xzste0jX9BqK1s6jWaGg1sR3KpvfS8mNlUOlC3hUzI-y0FVDeW2FDBNc6lGumlgF4q0EttEvIJiTSNxPLY4UK7-qmitCkNIBYbARRFbYSrAUL5yhkLWLKWoNTglYdbEqsos7265rCEvJ1ug7ShC0U3vl2PY7jARyfkYOSIaSaA7AD-FDwhcodXdqa6e6dZnIeK3lmGiTocXny0Zavred30L44m1vuPX_fy5q9-Re7nKBhYxTI9JHvDau1fA-IazJsgVr8BP90nOg
  priority: 102
  providerName: ProQuest
– databaseName: HAS SpringerNature Open Access 2022
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_HHaI-iN9WT4ngmxdsk3SbPq7icSzoix7cW8hXdeE2u2y7ePffO5N-6OIh-lTapu2QmUl-6cz8QsgbWDQACracWeUsk74omPVgy7ZyTrkm8NpiofCnz7Ozc7m4KC8OCB9rYVLSfqK0TMP0mB32roWJBovBuGSJwosBbjxSleDgjEfz-eLLYvqzgrErWdRDhUwu1A0P781Ciaz_JoT5Z6LkFC29S27v4sZc_zCXl79NSKf3yb0BSdJ5L_sDchDiQ3Kr31vy-hFpwfMx4Tx4Gq6GbNdI1w3dAF5eGbpablnNxIaa6Ckoj1UWz5aR4qbSBpQcOrMCDEp3baB-IOlMrZddS8eKSooJIJhuhNbzmJyffvz64YwNOywwJ2veMd643JW1nIXKVbB2milhhA9KWsGdKWo4WsBERuZBWCU8gA3lKgswzxcpAPeEHMZ1DM8IdbXLg8EfihYWHVyZoIIoZy5XHgbVUmXk7djjetMTaegUABdK9_rRoB-d9KOvMvIelTK1RBLsdGG9_aYHo9AGoCrS_ZdlY6VvACiF2lsHiLFRMHTBJ49HlerBM1stAAGj5Fxm5PV0G3wKAyUmhvWubyMkvjojT3sLmCQB_AYgpxQZUXu2sSfq_p24_J54u4sCy3EEfPhkNKNfcv2tL04mU_uHrnv-f29_Qe5wdAzkrsyPyWG33YWXgLM6-2pwrJ_yoiIL
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFD4anRDjgTsjMJCReGMuSZyL8zgQ04TExAMV48nyLVCxplWTiI5fz7FzgcKE2FPU5LR2jj_bn3tuAC_w0IAsWMVUca1oYqKIKoNYVrnWXJc2LpQLFH5_mp3Mkndn6dkOZEMsjHfa9ykt_TI9eIe9qnGjccFgcUJ9Ci-6ma5MeQ12M2dYmsDu7PTD0WdXSQ45CkWaEPcRMiHjl3x5axfyyfovY5h_O0qO1tKbcKOtVvLiuzw__21DOr4Nn4ZX6fxQvk3bRk31jz-yPF79Xe_ArZ6jkqNO8i7s2OoeXO-qVl7chxrXFOfKbg2xm96PtiLLkqyQiS8kWczXtKBsRWRlCMKC5sp9mlfElauWCB_byAWyW9LWlpg-_aeXnjc1GWI1iXMtcY5MDpcPYHb89uObE9rXbqA6KeKGxqUOdVokmc11jqeyjDPJjOWJYrGWUYFXhWxLJqFlijODNIbrXCGBNJE37T2ESbWs7CMgutChle6vSoXHmZhLyy1LMx1yg8t1ygN4OYylWHUpOoQ3rTMuOlUKVKXwqhSbAF674R4lXXptf2O5_iL6IRASSbArJJCmpUpMiRTMFkZp5KIlx0URmzwYwCL6OV8Lhtza9TxOAng-PsbZ6kwwsrLLtpNhifvpAPY7bI09QWaI9CllAfAt1G11dftJNf_qM4JHkQv0Ydjw4QDQX_36ly4ORxD_h-oeX038CezFDsMuK2Z4AJNm3dqnyOAa9ayfrj8BG7xAaA
  priority: 102
  providerName: Unpaywall
Title Increased expression of plasma mir-9-3p and let-7b-3p in methamphetamine use disorder and its clinical significance
URI https://link.springer.com/article/10.1038/s41598-024-81921-x
https://www.ncbi.nlm.nih.gov/pubmed/39738153
https://www.proquest.com/docview/3150195324
https://www.proquest.com/docview/3150346186
https://pubmed.ncbi.nlm.nih.gov/PMC11686234
https://www.nature.com/articles/s41598-024-81921-x.pdf
https://doaj.org/article/a533618655fb4df283e9dbc105f83078
UnpaywallVersion publishedVersion
Volume 14
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVFSB
  databaseName: Free Full-Text Journals in Chemistry
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: HH5
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://abc-chemistry.org/
  providerName: ABC ChemistRy
– providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: KQ8
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: ABDBF
  dateStart: 20121221
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DIK
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: RPM
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVAQT
  databaseName: Springer Nature - nature.com Journals - Fully Open Access
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: NAO
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: https://www.nature.com/siteindex/index.html
  providerName: Nature Publishing
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20210101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20210101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVFZP
  databaseName: Scholars Portal Journals: Open Access
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 20250131
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M48
  dateStart: 20110801
  isFulltext: true
  titleUrlDefault: http://journals.scholarsportal.info
  providerName: Scholars Portal
– providerCode: PRVAVX
  databaseName: HAS SpringerNature Open Access 2022
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: AAJSJ
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: https://www.springernature.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: Springer Nature OA Free Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: C6C
  dateStart: 20111201
  isFulltext: true
  titleUrlDefault: http://www.springeropen.com/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGJsR4QNwXGJWReGNmie0kzgNCXbVpqrRqAiqVp8i3QKU2LU0q2n_PcW5QUSHEU5TYbY58vmN_js8FoTewaQAWrChRQivCTRAQZQDLKtZa6MzSRLlA4ZtRdD3mw0k4OUBtuaNmAIu9WztXT2q8mr3bfN9-AIN_X4eMi_MCFiEXKEY5qdJ7EeCUR7AyUYfym4bu17m-acKDpImd2f_TnfWpSuO_j3v-6ULZnaPeR_fW-VJuf8jZ7Lel6uohetBwTNyvQfEIHdj8MbpbV53cPkEFzAnOFd0abDeNH2yOFxleApOeSzyfrkhC2BLL3GBQK4mVu5vm2JWblqB-W8o5sFO8Liw2TfrOqve0LHAba4mda4hzRHK4eorGV5efB9ekqb1ANE9oSWimfR0mPLKxjmFXFQkmmbGCK0a1DBK4KmBLkvuWKcEM0BChYwUE0ATV0dwzdJgvcnuCsE60b6X71KhgO0KFtMKyMNK-MDDdhsJDb9sRT5d1io20OhpnIq31k4J-0ko_6cZDF04pXU-XHrt6sFh9TRtrSyWQWFcIIAwzxU0GFMomRmngkpmASQ1eedqqNG0hlzLgxk5yyj30umsGa3NHKDK3i3Xdh3H31x56XiOgkwSYHdCfkHlI7GBjR9Tdlnz6rcroHQQuUIfBi89aGP2S629jcdZB7R-G7sX_C_YSHVNnJC7DpX-KDsvV2r4CNlaqHroTT-IeOur3h5-GcL24HN1-hKeDaNCrvnD0KiOElvHotv_lJ_pjOS8
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEBoIIRi3wgAjwROzlthO4zwgxG3q2OVpk_bm-RaotKalabX2T_EbOSe3UYEmXvbYxkqcnM_H3_G5EfIGjAZgwZYzq5xl0scxsx6wbFPnlMsDzywmCh8e9Qcn8ttpcrpGfrW5MBhW2erESlH7scMz8h0BzAVdPlx-mPxk2DUKvattC40aFvtheQEmW_l-7wvI9y3nu1-PPw9Y01WAOZnxGeO5i1ySyX5IXQr2Ql8JI3xQ0gruDNj0VljgAUZGQVglPGywyqUWqI2PK6cT3PcGuSlFJLFWf3qadmc66DWTcdbk5kRC7ZSwP2IOG5esqjzGFiv7X9Um4F_c9u8Qzc5Pe4dszIuJWV6Y8_M_tsLd--Rew2Hpxxp0D8haKDbJrbqr5XKT3K2PAmmd4fSQlKCDMPQ9eBoWTdxtQcc5nQBzHxk6Gk5ZxsSEmsJTgBFLLf4aFhTbWxuAW5iZEbBhOi8D9U250Gr0cFbSNreTYigKBj4hjh-Rk2uRymOyXoyL8JRQl7koGDzatGD-cGWCCiLpu0h5UO-J6pF3rQT0pC7poStXvFC6lpcGeelKXnrRI59QSN1ILMdd_TGeftfN6tYGSDM2HkiS3EqfA2ULmbcOuGuuQInCI7daEetGR5T6EtE98rq7DKsbXTamCON5PUZIvHWPPKkR0c0EmCTQrUT0iFrByspUV68Uwx9VBfE4xsQgAQ_ebmF1Oa-rvsV2B73_-HTPrn7rV2RjcHx4oA_2jvafk9scFwlW0Iy2yPpsOg8vgO3N7MtqiVFydt1r-jfY0GJk
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEDchBONWGGAkeGJWE9tpnAeEgDFtDCYemNQ341ug0pqWptXav8av45zcRgWaeNljGytxcr5z_NnnRsgL2DQAC7acWeUskz6OmfWAZZs6p1weeGYxUfjz0WD_WH4cJsMN8qvNhcGwytYmVobaTxyekfcFMBd0-XDZz5uwiC-7e2-mPxl2kEJPa9tOo4bIYVidwvatfH2wC7J-yfneh6_v91nTYYA5mfE547mLXJLJQUhdCnuHgRJG-KCkFdwZ2N9bYYETGBkFYZXwsNgql1qgOT6uHFBw30vkciqkwHCydJh25zvoQZNx1uTpREL1S1grMZ-NS1ZVIWPLtbWwahnwL577d7hm57O9Qa4tiqlZnZqTkz-Wxb3b5FbDZ-nbGoB3yEYotsiVusPlaovcrI8FaZ3tdJeUYI8wDD54GpZNDG5BJzmdAosfGzoezVjGxJSawlOAFEst_hoVFFtdG4BemJsxMGO6KAP1TenQavRoXtI2z5NiWAoGQSGm75HjC5HKfbJZTIrwkFCXuSgYPOa0sBXiygQVRDJwkfJg6hPVI69aCehpXd5DV255oXQtLw3y0pW89LJH3qGQupFYmrv6YzL7rhtN1wYINDYhSJLcSp8DfQuZtw54bK7AoMIjt1sR68ZelPoM3T3yvLsMmo7uG1OEyaIeIyTeukce1IjoZgKsEqhXInpErWFlbarrV4rRj6qaeBxjkpCAB--0sDqb13nfYqeD3n98ukfnv_UzchW0WX86ODp8TK5z1BEsphltk835bBGeAPGb26eVhlHy7aJV-je9vGaf
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bb9MwFD4anRDjgTsjMJCReGMuSZyL8zgQ04TExAMV48nyLVCxplWTiI5fz7FzgcKE2FPU5LR2jj_bn3tuAC_w0IAsWMVUca1oYqKIKoNYVrnWXJc2LpQLFH5_mp3Mkndn6dkOZEMsjHfa9ykt_TI9eIe9qnGjccFgcUJ9Ci-6ma5MeQ12M2dYmsDu7PTD0WdXSQ45CkWaEPcRMiHjl3x5axfyyfovY5h_O0qO1tKbcKOtVvLiuzw__21DOr4Nn4ZX6fxQvk3bRk31jz-yPF79Xe_ArZ6jkqNO8i7s2OoeXO-qVl7chxrXFOfKbg2xm96PtiLLkqyQiS8kWczXtKBsRWRlCMKC5sp9mlfElauWCB_byAWyW9LWlpg-_aeXnjc1GWI1iXMtcY5MDpcPYHb89uObE9rXbqA6KeKGxqUOdVokmc11jqeyjDPJjOWJYrGWUYFXhWxLJqFlijODNIbrXCGBNJE37T2ESbWs7CMgutChle6vSoXHmZhLyy1LMx1yg8t1ygN4OYylWHUpOoQ3rTMuOlUKVKXwqhSbAF674R4lXXptf2O5_iL6IRASSbArJJCmpUpMiRTMFkZp5KIlx0URmzwYwCL6OV8Lhtza9TxOAng-PsbZ6kwwsrLLtpNhifvpAPY7bI09QWaI9CllAfAt1G11dftJNf_qM4JHkQv0Ydjw4QDQX_36ly4ORxD_h-oeX038CezFDsMuK2Z4AJNm3dqnyOAa9ayfrj8BG7xAaA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+expression+of+plasma+mir-9-3p+and+let-7b-3p+in+methamphetamine+use+disorder+and+its+clinical+significance&rft.jtitle=Scientific+reports&rft.au=Wang%2C+Wei&rft.au=Li%2C+Chen&rft.au=Sun%2C+Guangsheng&rft.au=Qiu%2C+Cunxi&rft.date=2024-12-30&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=14&rft_id=info:doi/10.1038%2Fs41598-024-81921-x&rft.externalDocID=PMC11686234
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon